Welcome to our dedicated page for Alignment Healthcare SEC filings (Ticker: ALHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alignment Healthcare, Inc.'s SEC filings document a Medicare Advantage operating company with common stock listed on Nasdaq under ALHC. Its Form 8-K reports furnish quarterly and annual operating results, health plan membership, revenue, adjusted gross profit, adjusted EBITDA, guidance updates and Regulation FD materials related to strategy, market position and Medicare Advantage quality ratings.
Proxy materials cover board elections, executive compensation, equity awards, pay-versus-performance data and shareholder voting matters. Registration statements, prospectus supplements and underwriting agreements describe secondary offerings of common stock by selling stockholders, the company's capital structure and related securities-law obligations.
Wellington Management Group and affiliates report a significant institutional stake in Alignment Healthcare, Inc. They beneficially own 14,070,893 shares of Alignment Healthcare common stock, representing about 7.3%–7.34% of the class as of 12/31/2025.
The shares are owned of record by clients of various Wellington investment advisers, while the Wellington entities report shared voting and shared dispositive power over most of these shares and no sole power. They state the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Alignment Healthcare.
Alignment Healthcare, Inc. filed a notice of proposed sale of 22,500 shares of its common stock under Rule 144. The planned sale through E-Trade Finance has an aggregate market value of $489,375 and is targeted for around February 10, 2026 on the Nasdaq Stock Market.
The seller previously acquired 38,941 common shares on February 7, 2024 as a stock award under the company’s 2021 Equity Incentive Plan. Shares outstanding were 200,091,742 at the time referenced, providing context for the scale of the planned sale.
FMR LLC has disclosed a significant passive ownership stake in Alignment Healthcare Inc. common stock. As of December 31, 2025, FMR LLC and related reporting person Abigail P. Johnson beneficially owned 14,792,081.57 shares, representing 7.7% of Alignment Healthcare’s outstanding common stock.
FMR LLC reports sole voting power over 14,776,171.28 shares and sole dispositive power over 14,792,081.57 shares, with no shared voting or dispositive power. The securities are certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
The Vanguard Group reports beneficial ownership of 15,492,802 shares of Alignment Healthcare Inc common stock, representing 7.74% of the class as of the reported date. Vanguard has shared voting power over 1,275,363 shares and shared dispositive power over all 15,492,802 shares, with no sole voting or dispositive power.
The holdings are managed in the ordinary course of business and not for the purpose of changing or influencing control of Alignment Healthcare. Vanguard’s clients have the right to receive dividends and sale proceeds from these securities, and no single client holds more than 5% of the class. Vanguard also notes an internal realignment on January 12, 2026, after which certain subsidiaries are expected to report beneficial ownership separately.
Alignment Healthcare, Inc. executive Adnan R. Mansour, the company’s Chief Digital Officer, filed an initial insider ownership report. This filing states that he does not beneficially own any Alignment Healthcare securities. Both the non-derivative and derivative securities tables show no holdings, and the remarks section explicitly notes that no securities are beneficially owned. The form is filed as a single-reporting-person filing and is signed by an attorney-in-fact under a power of attorney.
Alignment Healthcare president Dawn Christine Maroney reported insider sales of company stock. On 01/15/2026, she sold 15,129 shares of common stock at a weighted-average price of $22.1875 per share and an additional 14,871 shares at a weighted-average price of $22.781 per share.
The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on 05/22/2025. The prices reflect multiple trades, with per‑share prices ranging from $21.58 to $22.57 for the first group and $22.58 to $22.98 for the second. After these sales, Maroney directly owned 1,027,015 shares of Alignment Healthcare common stock.
Alignment Healthcare CEO share transactions: Shares associated with Chief Executive Officer and director John E. Kao, held indirectly through the JEK Trust for which he serves as trustee, were sold in two transactions on 01/12/2026 under a Rule 10b5-1 trading plan adopted on 03/12/2025. The trust sold 177,273 shares of common stock at a weighted-average price of $21.0997 per share and an additional 2,727 shares at a weighted-average price of $21.5665 per share, with individual trades occurring within the disclosed price ranges.
Following these sales, indirect holdings reported as held by the JEK Trust totaled 2,832,641 shares, and direct holdings reported in John Kao’s name totaled 1,568,379 shares of Alignment Healthcare common stock.
Alignment Healthcare, Inc. used a current report to update its growth outlook and reaffirm guidance. The company estimates about 275,300 health plan members as of January 1, 2026, which it states is roughly 31% growth versus January 1, 2025. It also expects 290,000 to 296,000 members by December 31, 2026, or about 24% to 27% growth relative to the midpoint of its latest 2025 year-end membership guidance.
The company also says current consensus for 2026 adjusted EBITDA of approximately $145 million will fall within its planned full-year 2026 guidance range, which it intends to provide with its fourth-quarter 2025 earnings. For 2025, it reaffirms prior guidance, including health plan membership of 232,500 to 234,500, revenue of $3,931 million to $3,946 million, adjusted gross profit of $474 million to $483 million, and adjusted EBITDA of $90 million to $98 million.
ALHC submitted a Form 144 notice covering a planned sale of 318,152 shares of common stock, with an aggregate market value of $6,681,192.00. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, where the stock is listed, with an approximate sale date of 01/06/2026. The filing notes that 200,091,742 shares of common stock were outstanding.
The seller acquired 228,152 common shares on 12/31/2025 via performance stock units and 90,000 common shares on 09/30/2019 through restricted and performance stock units, both from the issuer. Over the past three months, sales disclosed include 100,000 shares on 01/02/2026 for $2,003,450.00, and additional transactions in December 2025, some labeled as 10b5-1 sales for Dawn Maroney. The signatory represents they are not aware of undisclosed material adverse information about the issuer.
Alignment Healthcare president Dawn C. Maroney reported open-market sales of company common stock executed under a Rule 10b5-1 trading plan adopted on 05/22/2025. On December 12, 2025, she sold 16,681 shares at a weighted-average price of $20.0204 per share, leaving 1,780,556 shares directly owned. On December 15, 2025, she sold 113,319 shares at a weighted-average price of $20.0068 per share, and directly held 1,667,237 shares afterward. For each date, the weighted-average prices reflect multiple trades within narrow price ranges disclosed in the report.